BNF 82 (British National Formulary)

Format ORIGINAL PDF / PRINT REPLICA
Publisher ‏ : ‎ Pharmaceutical Press; 82nd edition (September 2, 2021)
Language ‏ : ‎ English
ISBN-10 ‏ : ‎ 0857114131
ISBN-13 ‏ : ‎ 978-0857114136

$26.99

SKU: original-pdf-bnf-82-british-national-formulary Category: Family, Primary care, hospital Medicine Tag: immunology

Description

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 82) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 82 edition include:

New monographs for:

COVID-19 vaccine for active immunisation against COVID-19 disease
Enhertu® [trastuzumab deruxtecan] for HER2-positive unresectable or metastatic breast cancer
Myalepta® [metreleptin] for leptin deficiency in lipodystrophy
Phesgo® [pertuzumab with trastuzumab] for HER2-positive early-stage, metastatic, or locally recurrent breast cancer
Treprostinil for idiopathic or hereditary pulmonary arterial hypertension
Trixeo Aerosphere® [formoterol fumarate with glycopyrronium and budesonide] and Bevespi Aerosphere® [glycopyrronium with formoterol fumarate] for chronic obstructive pulmonary disease
Von Willebrand Factor for von Willebrand disease

MHRA advice on:

Aminoglycosides: increased risk of deafness in patients with mitochondrial mutations
Dimethyl fumarate (Tecfidera®): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
Epilepsy: updated advice on antiepileptic drugs in pregnancy following comprehensive safety review
Erythromycin: caution required due to cardiac risks (QT interval prolongation) and drug interaction with rivaroxaban
Fingolimod (Gilenya®): updated advice about the risks of serious liver injury and herpes meningoencephalitis
Hydrocortisone (Alkindi®): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules
Medicines in pregnancy and breastfeeding: new initiative for consistent guidance and report on optimising data for medicines used during pregnancy
Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration
Tofacitinib (Xeljanz®▼): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors
Ulipristal acetate 5mg (Esmya®): further restrictions due to risk of serious liver injury
SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Other significant changes include updated guidance on:

COVID-19, including immunisation and recommendations on choice of COVID-19 vaccine in-line with Joint Committee on Vaccination and Immunisation and Public Health England recommendations
Management of hypoglycaemia, including age-based dose banding
Management of polycystic ovary syndrome
National flu immunisation programme and influenza vaccine in-line with Public Health England recommendations
Progestogen-only contraceptives in-line with Faculty of Sexual & Reproductive Healthcare recommendations
Treatment of human and animal bites
Use of hepatitis B immunoglobulin and vaccines in-line with Public Health England recommendations

BNF 82 is an essential publication, it provides you with:

Up-to-date information on prescribing, dispensing, and administering medicines
Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
Information you know you can trust for quality, reliability, and independence
Everything you need at your fingertips, all in one book

About PDF Formats (General)